Table 4.
Colonoscopy findings in colonoscopies during the pre-pandemic (2019) vs COVID periods (2020)
| Pre COVID2019 | First wave 2020 | Pre-COVID 2019 | Ramp up 2020 | |
|---|---|---|---|---|
| Number of cancers, n (%) | 44 (1.7) | 18 (3.9) | 33 (2.5%) | 31 (3.6%) |
| Location, n (%) | ||||
| Ileum | 0 (0%) | 1 (6%) | 3 (9.0%) | 3 (9.7%) |
| Cecum | 5 (11.4%) | 6 (33.3) | 7 (21.2%) | 3 (9.7%) |
| Ascending | 3 (6.8%) | 1 (5.6%) | 10 (30.3) | 5 (1.6%) |
| Transverse (includes flexures) | 6 (13.6%) | 1 (5.6%) | 2 (6.1%) | 1 (3.2%) |
| Descending | 3 (6.8%) | 1 (5.6%) | 5 (1.5%) | 4 (12.9%) |
| Sigmoid | 8 (18.2%) | 2 (11.1%) | 6 (1.8%) | 15 (58.4%) |
| Rectum | 18 (40.9%) | 5 (27.8%) | 0 (0%) | 0 (0%) |
| Other (inc. anastomosis) | 1 (2.3%) | 1 (5.6%) | 0 (0%) | 0 (0%) |
| Polyps removed, n (%)a | 929 (36.9%) | 167 (36.2%) | 489 (36.8%) | 350 (41.5%) |
| Adenoma removed, n (%)a | 766 (30.5%) | 142 (30.7%) | 351 (26.6%) | 252 (30.0%) |
| Type, n | ||||
| Hyperplastic | 210 | 35 | 46 | 23 |
| Tubular | 655 | 114 | 157 | 92 |
| Tubulovillous | 66 | 8 | 9 | 4 |
| Sessile serrated | 91 | 0 | 17 | 12 |
| High grade dysplasia | 27 | 0 | 15 | 14 |
| Inflammatory | 92 | 5 | 25 | 23 |
| Number of polyps, n (%)a | ||||
| 1 | 505 (20.1%) | 82 (17.8%) | 261 (19.6%) | 187 (22.2%) |
| 2 | 232 (9.2%) | 38 (8.2%) | 107 (8.1%) | 75 (8.9%) |
| 3 | 8 (3.5%) | 15 (3.3%) | 60 (4.5%) | 44 (5.2%) |
| 4 | 37 (1.5%) | 12 (2.6%) | 28 (21.1%) | 19 (2.3%) |
| 5–9 | 47 (10.2%) | 8 (1.7%) | 27 (20.3%) | 22 (2.6%) |
| > 10 | 18 (7.2%) | 8 (1.7%) | 6 (0.5%) | 3 (3.6%) |
| AJCC cancer stage | ||||
| 0 | – | – | 1 (3.0%) | 2 (6.5%) |
| I | – | – | 6 (18.2%) | 3 (9.6%) |
| 2 | – | – | 11 (33.3%) | 6 (20%) |
| 3 | – | – | 8 (24.3%) | 7 (22.6%) |
| 4 | – | – | 4 (12.1%) | 9 (29.0%) |
| Stage unavailable | – | – | 2 (6.1%) | 1 (3.4%) |
| Non-adenocarcinomas | – | – | 1 (3.0%) | 3 (9.6%) |
aPrecentage of positive finding per colonoscopies completed in each period